6bi2: Difference between revisions

From Proteopedia
Jump to navigationJump to search
OCA (talk | contribs)
m Protected "6bi2" [edit=sysop:move=sysop]
OCA (talk | contribs)
No edit summary
 
(4 intermediate revisions by the same user not shown)
Line 1: Line 1:
'''Unreleased structure'''


The entry 6bi2 is ON HOLD
==Trastuzumab Fab D185A (Light Chain) Mutant Biotin Conjugation.==
<StructureSection load='6bi2' size='340' side='right'caption='[[6bi2]], [[Resolution|resolution]] 1.80&Aring;' scene=''>
== Structural highlights ==
<table><tr><td colspan='2'>[[6bi2]] is a 4 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6BI2 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6BI2 FirstGlance]. <br>
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.801&#8491;</td></tr>
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=BTN:BIOTIN'>BTN</scene>, <scene name='pdbligand=EDO:1,2-ETHANEDIOL'>EDO</scene></td></tr>
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6bi2 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6bi2 OCA], [https://pdbe.org/6bi2 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6bi2 RCSB], [https://www.ebi.ac.uk/pdbsum/6bi2 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6bi2 ProSAT]</span></td></tr>
</table>
<div style="background-color:#fffaf0;">
== Publication Abstract from PubMed ==
Activated esters are widely used to label proteins at lysine sidechains and N-termini. These reagents are useful for labeling virtually any protein, but robust reactivity toward primary amines generally precludes site-selective modification. In a unique case, fluoro-phenyl esters are shown to preferentially label human kappa antibodies at a single lysine (K188) within the light chain constant domain. Neighboring residues H189 and D151 contribute to the accelerated rate of labeling at K188 relative to ~40 other lysine sites. Enriched K188 labeling can be enhanced from 50-70% to &gt;95% by any of these approaches: lowering reaction temperature, applying flow chemistry, or mutagenesis of specific residues in the surrounding protein environment. Our results demonstrate that activated esters with fluoro-substituted aromatic leaving groups, including a fluoro-napthyl ester, can be generally useful reagents for site-selective lysine labeling of antibodies and other immunoglobulin-type proteins.


Authors: DiDonato, M., Spraggon, G.
Tuning a Protein Labeling Reaction to Achieve Highly Site-Selective Lysine Conjugation.,Pham GH, Ou W, Bursulaya B, DiDonato M, Herath A, Jin Y, Hao X, Loren J, Spraggon G, Brock A, Uno T, Geierstanger BH, Cellitti S Chembiochem. 2018 Jan 31. doi: 10.1002/cbic.201700611. PMID:29388367<ref>PMID:29388367</ref>


Description: Trastuzumab Fab D185A (Light Chain) Mutant Biotin Conjugation.
From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
[[Category: Unreleased Structures]]
</div>
[[Category: Spraggon, G]]
<div class="pdbe-citations 6bi2" style="background-color:#fffaf0;"></div>
[[Category: Didonato, M]]
== References ==
<references/>
__TOC__
</StructureSection>
[[Category: Homo sapiens]]
[[Category: Large Structures]]
[[Category: DiDonato M]]
[[Category: Spraggon G]]